

<i>To submit comments:</i>	<i>Send them to:</i>
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Under Section 7003(d) of the Resource Conservation and Recovery Act (“RCRA”), a commenter may request an opportunity for a public meeting in the affected area.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http://www.usdoj.gov/enrd/Consent_Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$22.25 (25 cents per page reproduction cost) payable to the United States Treasury. For a paper copy without the appendices and signature pages, the cost is \$16.00.

Maureen M. Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2013–21850 Filed 9–6–13; 8:45 am]

BILLING CODE 4410–15–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–378]

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice.

SUMMARY: This notice establishes the initial 2014 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: *Effective:* September 9, 2013.

FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy Evaluation and Analysis Section, Office of

Diversion Control, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152, Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Background

Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has re delegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104.

The 2014 aggregate production quotas and assessment of annual needs represent those quantities of Schedules I and II controlled substances and the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured in the United States in 2014 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes.

On July 3, 2013, a notice titled, “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014,” was published in the **Federal Register** (78 FR 40186). That notice proposed the 2014 aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and the 2014 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 2, 2013.

Comments Received

DEA received seven comments from DEA-registered manufacturers within the published comment period on a total of 23 Schedule I and II controlled substances and one List I chemical. Commenters stated that the proposed

aggregate production quotas for (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11), N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), cathinone, amphetamine (for sale), codeine (for conversion), codeine (for sale), fentanyl, hydrocodone (for sale), hydromorphone, levomethorphan, methylphenidate, morphine (for conversion), morphine (for sale), noroxymorphone (for conversion), oripavine, oxycodone (for sale), oxymorphone (for conversion), oxymorphone (for sale), phenylacetone, tapentadol, tetrahydrocannabinol, and thebaine were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. One commenter stated that the proposed assessment of annual needs quota for phenylpropanolamine (for conversion) was insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks.

Determination of 2014 Aggregate Production Quotas and Assessment of Annual Needs

In determining the 2014 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the consideration of 2013 manufacturing quotas, current 2013 sales and inventories, 2014 export requirements, industrial use, additional applications for quotas, as well as information on research and product development requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas and assessment of annual needs for 1-[1-(2-Thienyl)cyclohexyl]piperidine, carfentanil, cathinone, dihydromorphone, dimethyltryptamine, ecgonine, hydromorphone, levomethorphan, lysergic acid diethylamide, metazocine, methamphetamine, d-methamphetamine (for conversion), methyl-desorphan, noroxymorphone (for conversion), oxymorphone (for conversion), phencyclidine, phenylacetone, ephedrine (for conversion), ephedrine (for sale),

phenylpropanolamine (for conversion), and pseudoephedrine (for sale) are warranted. This notice reflects those adjustments.

Regarding (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11), N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), amphetamine (for sale), codeine (for conversion), codeine (for sale), fentanyl, hydrocodone (for sale), methylphenidate, morphine (for conversion), morphine (for sale), oripavine, oxycodone (for sale), oxymorphone (for sale), tapentadol, tetrahydrocannabinol, thebaine, and phenylpropanolamine (for sale), the DEA has determined that the proposed initial 2014 aggregate production quotas and assessment of annual needs are sufficient to meet the current 2014 estimated medical, scientific, research,

and industrial needs of the United States. This notice finalizes these aggregate production quotas at the same amounts as proposed.

DEA also specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA included in all Schedule II aggregate production quotas, and certain Schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The established aggregate production quotas reflect these included amounts. This

action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances.

In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Deputy Administrator hereby establishes the 2014 aggregate production quotas for the following Schedule I and II controlled substances and the 2014 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic Class—Schedule I	Established 2014 Quotas (grams)
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)	15
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11)	15
1-(1-Phenylcyclohexyl)pyrrolidine	10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	45
1-[1-(2-Thienyl)cyclohexyl]piperidine	15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	45
1-Butyl-3-(1-naphthoyl)indole (JWH-073)	45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)	45
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)	45
1-Methyl-4-phenyl-4-propionoxypiperidine	2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)	45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)	45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)	45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)	45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)	45
1-Pentyl-3-[[4-methoxy-benzoyl]indole (SR-19, RCS-4)	45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)	45
2-(2,5-Dimethoxy-4-(n-propylphenyl)ethanamine (2C-P)	30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)	30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)	30
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	30
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	30
2,5-Dimethoxy-4-ethylamphetamine (DOET)	25
2,5-Dimethoxy-4-n-propylthiophenethylamine	25
2,5-Dimethoxyamphetamine	25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	30
3,4,5-Trimethoxyamphetamine	25
3,4-Methylenedioxyamphetamine (MDA)	55
3,4-Methylenedioxyamphetamin (MDMA)	50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	40
3,4-Methylenedioxy-N-methylcathinone (methylone)	50
3,4-Methylenedioxypropylvalerone (MDPV)	35
3-Methylfentanyl	2
3-Methylthiofentanyl	2
4-Bromo-2,5-dimethoxyamphetamine (DOB)	25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)	25
4-Methoxyamphetamine	100
4-Methyl-2,5-dimethoxyamphetamine (DOM)	25
4-Methylaminorex	25

Basic Class—Schedule I	Established 2014 Quotas (grams)
4-Methyl-N-methylcathinone (mephedrone)	45
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	68
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47, 497 C8-homolog)	53
5-Methoxy-3,4-methylenedioxyamphetamine	25
5-Methoxy-N,N-diisopropyltryptamine	25
5-Methoxy-N,N-dimethyltryptamine	25
Acetyl-alpha-methylfentanyl	2
Acetyldihydrocodeine	2
Acetylmethadol	2
Allylprodine	2
Alphacetylmethadol	2
Alpha-ethyltryptamine	25
Alphameprodine	2
Alphamethadol	2
Alpha-methylfentanyl	2
Alpha-methylthiofentanyl	2
Alpha-methyltryptamine (AMT)	25
Aminorex	25
Benzylmorphine	2
Betacetylmethadol	2
Beta-hydroxy-3-methylfentanyl	2
Beta-hydroxyfentanyl	2
Betameprodine	2
Betaprodine	2
Bufotenine	3
Cathinone	70
Codeine Methylbromide	5
Codeine-N-oxide	200
Desomorphine	5
Diethyltryptamine	25
Difenoxin	50
Dihydromorphine	3,990,000
Dimethyltryptamine	35
Dipipanone	5
Fenethylamine	5
Gamma-hydroxybutyric acid	70,250,000
Heroin	25
Hydromorphanol	2
Hydroxypethidine	2
Ibogaine	5
Lysergic acid diethylamide (LSD)	35
Marihuana	21,000
Mescaline	25
Methaqualone	10
Methcathinone	25
Methyl-desorphine	2
Methyldihydromorphine	2
Morphine Methylbromide	5
Morphine Methylsulfonate	5
Morphine-N-oxide	175
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48)	15
N-Benzylpiperazine	25
N,N-Dimethylamphetamine	25
N-Ethyl-1-phenylcyclohexylamine	5
N-Ethylamphetamine	24
N-Hydroxy-3,4-methylenedioxyamphetamine	24
Noracetylmethadol	2
Norlevorphanol	52
Normethadone	2
Normorphine	18
Para-fluorofentanyl	2
Parahexyl	5
Phenomorphan	2
Pholcodine	2
Propriodine	2
Psilocybin	30
Psilocyn	30
Tetrahydrocannabinols	491,000
Thiofentanyl	2
Tilidine	10
Trimeperidine	2

Basic Class—Schedule II	Established 2014 Quotas (grams)
1-Phenylcyclohexylamine	3
1-Piperidinocyclohexanecarbonitrile (PCC)	3
4-Anilino-N-phenethyl-4-piperidine (ANPP)	2,687,500
Alfentanil	17,625
Alphaprodine	3
Amobarbital	9
Amphetamine (for conversion)	18,375,000
Amphetamine (for sale)	49,000,000
Carfentanil	19
Cocaine	240,000
Codeine (for conversion)	68,750,000
Codeine (for sale)	46,125,000
Dextropropoxyphene	19
Dihydrocodeine	100,750
Diphenoxylate	750,000
Ecgonine	144,000
Ethylmorphine	3
Fentanyl	2,108,750
Glutethimide	3
Hydrocodone (for sale)	99,625,000
Hydromorphone	6,750,000
Isomethadone	5
Levo-alphaacetylmethadol (LAAM)	4
Levomethorphan	195
Levorphanol	2,000
Lisdexamfetamine	23,750,000
Meperidine	6,250,000
Meperidine Intermediate-A	6
Meperidine Intermediate-B	11
Meperidine Intermediate-C	6
Metazocine	19
Methadone (for sale)	31,875,000
Methadone Intermediate	38,875,000
Methamphetamine	2,811,375
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,500,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]	
Methylphenidate	96,750,000
Morphine (for conversion)	91,250,000
Morphine (for sale)	62,500,000
Nabilone	30,375
Noroxymorphone (for conversion)	17,500,000
Noroxymorphone (for sale)	1,462,500
Opium (powder)	112,500
Opium (tincture)	625,000
Oripavine	22,750,000
Oxycodone (for conversion)	9,250,000
Oxycodone (for sale)	149,375,000
Oxymorphone (for conversion)	25,000,000
Oxymorphone (for sale)	7,750,000
Pentobarbital	35,000,000
Phenazocine	6
Phencyclidine	19
Phenmetrazine	3
Phenylacetone	67,000,000
Racemethorphan	3
Remifentanil	3,750
Secobarbital	215,003
Sufentanil	6,255
Tapentadol	17,500,000
Thebaine	145,000,000
Basic Class—List I Chemicals	Proposed 2014 Quotas
Ephedrine (for conversion)	1,000,000
Ephedrine (for sale)	3,000,000
Phenylpropanolamine (for conversion)	44,800,000
Phenylpropanolamine (for sale)	5,300,000
Pseudoephedrine (for conversion)	5,000
Pseudoephedrine (for sale)	192,000,000

The Deputy Administrator also establishes aggregate production quotas for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. Pursuant to 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2014 aggregate production quotas and assessment of annual needs as needed.

Dated: August 30, 2013.

Thomas M. Harrigan,
Deputy Administrator.

[FR Doc. 2013-21797 Filed 9-6-13; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF LABOR

Employee Benefits Security Administration

[Application No. D-11758]

Notice of Proposed Exemption involving AT&T Inc. (Together With AT&T Inc.'s Affiliates, AT&T or the Applicant) Located in Dallas, TX

AGENCY: Employee Benefits Security Administration, U.S. Department of Labor.

ACTION: Notice of Proposed Exemption.

SUMMARY: This document contains a notice of pendency before the Department of Labor (the Department) of a proposed individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974, as amended (ERISA or the Act), and the Internal Revenue Code of 1986, as amended (the Code). The proposed transactions involve AT&T, the AT&T Pension Benefit Plan (the Plan), and the SBC Master Pension Trust (the Trust). The proposed exemption, if granted, would affect the Plan and its participants and beneficiaries.

Effective Date: If granted, this proposed exemption will be effective as of September 1, 2013.

DATES: Written comments and requests for a public hearing on the proposed exemption should be submitted to the Department within 55 days from the date of publication of this **Federal Register** Notice.

ADDRESSES: Comments and requests for a hearing should state: (1) The name, address, and telephone number of the person making the comment or request, and (2) the nature of the person's interest in the proposed exemption and the manner in which the person would be adversely affected by the exemption, if granted. A request for a hearing must also state the issues to be addressed and

include a general description of the evidence to be presented at the hearing. All written comments and requests for a public hearing concerning the proposed exemption should be sent to the Office of Exemption Determinations, Employee Benefits Security Administration, Room N-5700, U.S. Department of Labor, 200 Constitution Avenue NW., Washington DC 20210, Attention: Application No. D-11758. Interested persons are also invited to submit comments and/or hearing requests to EBSA via email or FAX. Any such comments or requests should be sent either by email to: moffitt.betty@dol.gov, or by FAX to (202) 219-0204 by the end of the scheduled comment period. The application for exemption and the comments received will be available for public inspection in the Public Documents Room of the Employee Benefits Security Administration, U.S. Department of Labor, Room N-1513, 200 Constitution Avenue NW., Washington, DC 20210. Comments and hearing requests will also be available online at www.regulations.gov and www.dol.gov/ebbsa, at no charge.

Warning: If you submit written comments or hearing requests, do not include any personally identifiable information (such as name, address, or other contact information) or confidential business information that you do not want publicly disclosed. All comments and hearing requests may be posted on the Internet and can be retrieved by most Internet search engines.

FOR FURTHER INFORMATION CONTACT:

Anna Mpras Vaughan, Office of Exemption Determinations, Employee Benefits Security Administration, U.S. Department of Labor, telephone (202) 693-8565. (This is not a toll-free number.)

SUPPLEMENTARY INFORMATION: This document contains a notice of proposed exemption that, if granted, would provide exemptive relief from sections 406(a)(1)(A), 406(a)(1)(B), 406(a)(1)(D), 406(a)(1)(E), 406(a)(2), 406(b)(1), 406(b)(2), and 407(a) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A), 4975(c)(1)(B), 4975(c)(1)(D) and 4975(c)(1)(E) of the Code. The proposed exemption has been requested by AT&T pursuant to section 408(a) of the Act and section 4975(c)(2) of the Code, and in accordance with the procedures set forth in 29 CFR Part 2570, Subpart B (76 FR 66637, 66644, October 27, 2011). Effective December 31, 1978, section 102 of the Reorganization Plan No. 4 of 1978, 5

U.S.C. App. 1 (1996), transferred the authority of the Secretary of the Treasury to issue administrative exemptions under section 4975(c)(2) of the Code to the Secretary of Labor. Accordingly, this notice of proposed exemption is being issued solely by the Department.

Summary of Facts and Representations¹

Background

1. AT&T Inc. (together with its affiliates, AT&T), formerly known as SBC Communications Inc., is a holding company incorporated in 1983 under the laws of the State of Delaware that has its principal executive offices in Dallas, Texas. AT&T, a provider of telecommunications services, offers its services and products to consumers in the U.S. and to businesses and other providers of telecommunications services worldwide. The services and products that AT&T offers vary by market, and include: wireless communications, local exchange services, long-distance services, data/broadband and Internet services, video services, telecommunications equipment, managed networking and wholesale services.

2. AT&T is the sponsor of the AT&T Pension Benefit Plan (the Plan). Effective December 14, 2010, the Plan was amended (the 2010 Amendment) to name the Plan's named fiduciary, AT&T Services, as the plan administrator. AT&T Services, pursuant to delegation (the Delegation) from its Board of Directors (the Board) dated July 1, 2011, delegated to the AT&T Inc. Benefit Plan Investment Committee (the Committee) all powers and authority that may be necessary or appropriate to the establishment, qualification, administration, maintenance, and operation of the SBC Master Pension Trust (the Trust) established as part of the Plan. Notwithstanding its power to delegate authority, the Committee retains, and may not delegate, the authority to authorize "company-directed" investments (i.e., investments that have not been delegated to a third party investment manager) in amounts greater than \$200,000,000.

3. In addition to AT&T Services and the Committee, other Plan fiduciaries include Brock Fiduciary Services LLC (the Independent Fiduciary), an investment manager that is independent of AT&T Inc.

¹ The Summary of Facts and Representations is based on the Applicant's representations and does not reflect the views of the Department.